Statins have proved to reduce cardiovascular morbidity and mortality in high-risk population and are generally well tolerated, although adverse events can occur. Up to 3% of patients develop aminotransferases elevation, which usually normalizes with continued treatment and hardly is associated with clinical symptoms. Serious statin-related liver injury is exceedingly rare. Furthermore, literature regarding rechallenge with a second statin is extremely poor. Some authors caution that re-exposure to these drugs is associated with a more serious liver injury but safe switching to a second statin after drug-induced liver injury (DILI) is also reported. We describe a case of a middle-aged woman who developed hepatocellular liver injury after simvastatin dose escalation; a rechallenge with low dose rosuvastatin caused rapid recurrence of DILI. In our opinion, clinicians should be very cautious upon rechallenge and closely follow-up patients who experienced statin-induced liver injury when trying re-exposure to another statin.

A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect? / Onfiani, G.; Nascimbeni, F.; Carubbi, F.. - In: JOURNAL OF BASIC AND CLINICAL PHYSIOLOGY AND PHARMACOLOGY. - ISSN 0792-6855. - 32:6(2021), pp. 1151-1155. [10.1515/jbcpp-2021-0013]

A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?

Onfiani G.;Nascimbeni F.;Carubbi F.
2021

Abstract

Statins have proved to reduce cardiovascular morbidity and mortality in high-risk population and are generally well tolerated, although adverse events can occur. Up to 3% of patients develop aminotransferases elevation, which usually normalizes with continued treatment and hardly is associated with clinical symptoms. Serious statin-related liver injury is exceedingly rare. Furthermore, literature regarding rechallenge with a second statin is extremely poor. Some authors caution that re-exposure to these drugs is associated with a more serious liver injury but safe switching to a second statin after drug-induced liver injury (DILI) is also reported. We describe a case of a middle-aged woman who developed hepatocellular liver injury after simvastatin dose escalation; a rechallenge with low dose rosuvastatin caused rapid recurrence of DILI. In our opinion, clinicians should be very cautious upon rechallenge and closely follow-up patients who experienced statin-induced liver injury when trying re-exposure to another statin.
2021
32
6
1151
1155
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect? / Onfiani, G.; Nascimbeni, F.; Carubbi, F.. - In: JOURNAL OF BASIC AND CLINICAL PHYSIOLOGY AND PHARMACOLOGY. - ISSN 0792-6855. - 32:6(2021), pp. 1151-1155. [10.1515/jbcpp-2021-0013]
Onfiani, G.; Nascimbeni, F.; Carubbi, F.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1250605
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact